Tesamorelin
Tesamorelin is an FDA-approved synthetic analogue of GHRH indicated for HIV-associated lipodystrophy. It binds GHRH receptors in the pituitary, stimulating endogenous GH release, which in turn reduces visceral adipose tissue. Meta-analysis of randomized controlled trials in people with HIV confirms significant visceral fat reduction and favorable metabolic effects.
Acute growth-hormone pulse within roughly 30 to 60 minutes of dosing; body-composition effects build over weeks.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
A stabilized synthetic analog of growth hormone-releasing factor that stimulates the synthesis and release of endogenous growth hormone.
Pharmacokinetics
- Half-life (t½)
- 30 min
- Approximate plasma half-life
- Routes
- Subcutaneous
t½ 30 min · ~3% remaining at 2.5 h
Citations (7)
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trialsPubMed 2026
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitorsPubMed 2024
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionPubMed
- Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelinPubMed
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophyPubMed
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trialPubMed
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophyPubMed
Last reviewed: 2026-05-09
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesVisceral Fat
“Highly effective for deep abdominal fat”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- FDA-approved for reduction of excess abdominal fat in HIV-infected individuals with lipodystrophy
- Studied off-label for visceral adiposity and metabolic syndrome in non-HIV populations
- Investigated for cognitive and neuroprotective properties in research settings
Key Research Benefits
- Reduces visceral fat
- Increases IGF-1
- Improves lipid profile
- Nootropic effects
Potential Side Effects
Considerations and Cautions
- Contraindicated in active malignancy
- Contraindicated during pregnancy
- Avoid in patients with hypersensitivity to tesamorelin or mannitol
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- IGF-1: Primary downstream marker of growth-hormone-axis activity; the tesamorelin label advises monitoring.
- Fasting glucose / HbA1c: GH-axis stimulation can reduce insulin sensitivity over time.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
Quick Explainer
Tesamorelin by goal
Read Tesamorelin's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.